AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11128879 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of 7 or more portions of fresh vegetables per week
Number of subjects: 112
Study 11128879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary habits (portions of fish, chicken, fruits, milk, and potatoes consumed each week)
Number of subjects: 112
Study 8775399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide (300 micrograms)
Number of subjects: 39
Study 8775399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 1442614 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dofetilide (3 micrograms/kg loading dose over 15 minutes and 1.5 micrograms/kg maintenance dose over 45 minutes)
Number of subjects: 18
Study 1442614 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dofetilide (6 + 3 micrograms/kg)
Number of subjects: 18
Study 1442614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6727750 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 28
Study 6727750 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 28
Study 3522159 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 60
Study 3522159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31916830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sans Forgetica font
Number of subjects: 160
Study 31916830 — intervention group
Group type: COMPARATOR
Intervention: Control font (not specified)
Number of subjects: 160
Study 31680621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon β‐1a
Number of subjects: 235
Study 30727881 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg non-labeled ACT-541468 with 250 nCi of 14C-labeled ACT-541468
Number of subjects: 6
Study 28954840 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate, High-Fiber, Low-Fat Diet
Number of subjects: 3234
Study 28954840 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 3234
Study 28954840 — intervention group
Group type: COMPARATOR
Intervention: Intensive Lifestyle Intervention (ILS)
Number of subjects: 3234
Study 28954840 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLBO)
Number of subjects: 3234
Study 25985726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysregulated circulating miRNAs in symptomatic heart failure patients
Number of subjects: 42
Study 25985726 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-182, miR-200a*, miR-568
Number of subjects: 42
Study 25985726 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-155, miR-595
Number of subjects: 42
Study 23197844 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered counseling intervention
Number of subjects: 355
Study 23197844 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC) condition
Number of subjects: 355
Study 21233091 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-inch sleeping-head-up (SHU) for 6 weeks
Number of subjects: 100
Study 21233091 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard non-pharmacological measures)
Number of subjects: 100
Study 18070245 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/d
Number of subjects: 627
Study 18070245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study 17130328 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg x kg(‐1)) before and after cardiopulmonary bypass
Number of subjects: 60
Study 17130328 — intervention group
Group type: COMPARATOR
Intervention: Control (no steroid administration)
Number of subjects: 60
Study 12480972 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (Epo) given every 1-3 weeks to maintain hemoglobin at 12.5 g% and intravenous iron (Fe) as necessary.
Number of subjects: 179
Study 12480972 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (Epo) and intravenous iron (Fe) treatment.
Number of subjects: 179
Study 11054618 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 0
Study 11054618 — intervention group
Group type: COMPARATOR
Intervention: No ICD therapy
Number of subjects: 0
Study 9372462 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacts with stabilizing tendencies
Number of subjects: 38
Study 9372462 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacts with unstabilizing tendencies
Number of subjects: 38
Study 9372462 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacts with mechanically unstabilizing effects
Number of subjects: 38
Study 1609038 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone at a mean dose of 16.25 mg/day
Number of subjects: 41
Study 1609038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3928422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and intraduodenal amino acid infusion
Number of subjects: 16
Study 3928422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrajejunal amino acid infusion
Number of subjects: 16
Study 3928422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrajejunal hyperosmolar mannitol (850 mosmol/kg)
Number of subjects: 16
Study 3928422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrajejunal balloon distention (40 mmHg)
Number of subjects: 16
Study 3928422 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum gastrin levels
Number of subjects: 16
Study 3928422 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma amino acids
Number of subjects: 16
Study 31915146 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (MET-hours/week of moderate-to-vigorous physical activity)
Number of subjects: 9886
Study 31915146 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet quality (Healthy Eating Index - HEI-2015 score)
Number of subjects: 9886
Study 31915146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physical activity and diet quality
Number of subjects: 9886
Study 31915146 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity, diet quality, and their combination
Number of subjects: 9886
Study 30205315 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation (1500 mg/day for 8 weeks)
Number of subjects: 44
Study 30205315 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation
Number of subjects: 44
Study 30205315 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study 25963932 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation (tVNS)
Number of subjects: 49
Study 25963932 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS (stVNS)
Number of subjects: 49
Study 24071616 — intervention group
Group type: EXPERIMENTAL
Intervention: PVBs and propofol-based total intravenous anesthesia
Number of subjects: 66
Study 24071616 — intervention group
Group type: COMPARATOR
Intervention: Standardized general anesthesia (control group)
Number of subjects: 66
Study 22725946 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 65
Study 22725946 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 65
Study 20199550 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer application after repeated hand washing (5 different moisturizers)
Number of subjects: 132
Study 20199550 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer application (3 of the 5 products)
Number of subjects: 132
Study 20199550 — intervention group
Group type: COMPARATOR
Intervention: Soap alone (control group)
Number of subjects: 132
Study 18621090 — intervention group
Group type: EXPERIMENTAL
Intervention: BioDis method for drug release prediction
Number of subjects: 0
Study 18621090 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel pH- and time-based multi-unit formulations
Number of subjects: 0
Study 15763286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 27
Study 15763286 — intervention group
Group type: COMPARATOR
Intervention: Control group (age matched healthy controls)
Number of subjects: 27
Study 14594516 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-fentanyl (25 microg/h for 3 days, then titrated)
Number of subjects: 131
Study 14594516 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release oral morphine (30 mg every 12 h, then titrated)
Number of subjects: 131
Study 14594516 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-fentanyl
Number of subjects: 131
Study 14594516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 131
Study 11329100 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic therapy (2 days of cefuroxime 750 mg IV every 8 hours followed by 5 days of cefuroxime axetil 500 mg orally every 12 hours)
Number of subjects: 52
Study 11329100 — intervention group
Group type: COMPARATOR
Intervention: 10 days of antibiotic therapy (2 days of cefuroxime 750 mg IV every 8 hours followed by 8 days of cefuroxime axetil 500 mg orally every 12 hours)
Number of subjects: 52
Study 11329100 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 52
Study 7772359 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 1.5 mg/kg
Number of subjects: 40
Study 7772359 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 1.4 mg/kg
Number of subjects: 40
Study 7772359 — intervention group
Group type: EXPERIMENTAL
Intervention: nitroglycerin 2 micrograms/kg
Number of subjects: 40
Study 7772359 — intervention group
Group type: COMPARATOR
Intervention: saline 5 ml
Number of subjects: 40
Study 2127787 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 million units of interferon alfa-2b, subcutaneously thrice weekly for 6 months
Number of subjects: 80
Study 2127787 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa-2b, subcutaneously thrice weekly for 6 months
Number of subjects: 80
Study 2127787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 80
Study 2127787 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa-2b, after initial 24 weeks
Number of subjects: 80
Study 2127787 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 million units of interferon alfa-2b, after initial 24 weeks
Number of subjects: 80
Study 2127787 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa-2b
Number of subjects: 80
Study 2127787 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 million units of interferon alfa-2b
Number of subjects: 80
Study 2127787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients
Number of subjects: 80
Study 758627 — intervention group
Group type: EXPERIMENTAL
Intervention: Time constant of 0.1 sec
Number of subjects: 1
Study 758627 — intervention group
Group type: EXPERIMENTAL
Intervention: Time constant of 0.3 sec
Number of subjects: 1
Study 758627 — intervention group
Group type: EXPERIMENTAL
Intervention: Time constant of 1.0 sec
Number of subjects: 1
Study 758627 — intervention group
Group type: EXPERIMENTAL
Intervention: Time constant of 10.0 sec
Number of subjects: 1
Study 31831295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolisation (PAE)
Number of subjects: 80
Study 31831295 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 80
Study 30832619 — intervention group
Group type: EXPERIMENTAL
Intervention: ET@Home education intervention (brochures, postcards, DVDs, and text messages over six months)
Number of subjects: 1200
Study 30832619 — intervention group
Group type: COMPARATOR
Intervention: KPSC standard of care education
Number of subjects: 1200
Study 30388112 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered lyophilized fecal microbiota product (n = 31)
Number of subjects: 65
Study 30388112 — intervention group
Group type: COMPARATOR
Intervention: Frozen fecal microbiota product by enema (n = 34)
Number of subjects: 65
Study 30388112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products (lyophilized and frozen)
Number of subjects: 65
Study 27801415 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 42
Study 27801415 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 42
Study 24756362 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 11.25 mg
Number of subjects: 42
Study 24756362 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 30 mg
Number of subjects: 42
Study 23255643 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured resection technique (n=26)
Number of subjects: 52
Study 23255643 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap balancing technique (n=26)
Number of subjects: 52
Study 20640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter sales of antibiotics
Number of subjects: 510
Study 20640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection antibiotics
Number of subjects: 510
Study 20640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of penicillins including β-lactamase inhibitors
Number of subjects: 510
Study 20640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillins with extended spectrum
Number of subjects: 510
Study 20640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation cephalosporins
Number of subjects: 510
Study 20640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory conditions
Number of subjects: 510
Study 20640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and socioeconomic factors
Number of subjects: 510
Study 17998490 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (50 mg, alternate days)
Number of subjects: 5956
Study 17998490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5956
Study 14694248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 24
Study 14694248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12243918 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of oral amoxicillin
Number of subjects: 2000
Study 12243918 — intervention group
Group type: COMPARATOR
Intervention: 5 days of oral amoxicillin
Number of subjects: 2000
Study 9704770 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 0
Study 9704770 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational Hypertension
Number of subjects: 0
Study 9704770 — intervention group
Group type: COMPARATOR
Intervention: Normotensive Controls
Number of subjects: 0
Study 7991041 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg daily
Number of subjects: 40
Study 7991041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3288258 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin 100 MRCU/day
Number of subjects: 49
Study 3288258 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 49
Study 31112641 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (M; 6 mg/kg IM)
Number of subjects: 12
Study 31112641 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-butorphanol (MB; 3 mg/kg each IM)
Number of subjects: 12
Study 31112641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sedation)
Number of subjects: 12
Study 26125538 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (up to 150 mg/d for 4 weeks)
Number of subjects: 29
Study 24812897 — intervention group
Group type: EXPERIMENTAL
Intervention: Xifeng Zhidong Tablet (XZT)
Number of subjects: 160
Study 24812897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 22693734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity white phototherapy
Number of subjects: 101
Study 22693734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity yellow phototherapy
Number of subjects: 101
Study 22693734 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacotherapy
Number of subjects: 101
Study 20075148 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training and orthoses
Number of subjects: 17
Study 20075148 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training
Number of subjects: 17
Study 18616861 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 128
Study 18616861 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 128
Study 15569877 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 11459
Study 15569877 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and dipyridamole
Number of subjects: 11459
Study 15569877 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11459
Study 11890966 — intervention group
Group type: EXPERIMENTAL
Intervention: MSLT following PSG (MSLT-P)
Number of subjects: 20
Study 11890966 — intervention group
Group type: COMPARATOR
Intervention: MSLT without prior PSG (MSLT-N)
Number of subjects: 20
Study 11890966 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotonous vigilance task (VT)
Number of subjects: 20
Study 11890966 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 20
Study 11890966 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scales (VAS)
Number of subjects: 20
Study 8629589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alpha-beta blockade (doxazosin 4 mg/day plus metoprolol 6.25 mg, gradually increased to 50 mg twice daily)
Number of subjects: 30
Study 8629589 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol alone (6.25 mg, gradually increased to 50 mg twice daily)
Number of subjects: 30
Study 8629589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alpha-beta blockade (doxazosin plus metoprolol)
Number of subjects: 30
Study 2123759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian electrocautery
Number of subjects: 88
Study 2123759 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotrophins (hMG)
Number of subjects: 88
Study 2123759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure follicle stimulating hormone (FSH)
Number of subjects: 88
Study 6769450 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SAB)
Number of subjects: 100
Study 6769450 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 100
Study 31554765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1578
Study 31554765 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1578
Study 30184513 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D levels <10.0 ng/mL
Number of subjects: 785
Study 30184513 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum 25-hydroxyvitamin D levels
Number of subjects: 785
Study 30184513 — intervention group
Group type: EXPERIMENTAL
Intervention: Having T allele of Fok1
Number of subjects: 785
Study 30184513 — intervention group
Group type: EXPERIMENTAL
Intervention: Having bb genotype of Bsm1
Number of subjects: 785
Study 30184513 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between 25(OH)D and VDR gene polymorphisms (Fok1)
Number of subjects: 785
Study 30184513 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between 25(OH)D and VDR gene polymorphisms (Bsm1)
Number of subjects: 785
Study 28891788 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (EVG/COBI/FTC/TDF)
Number of subjects: 575
Study 28891788 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF (ATV + RTV + FTC/TDF)
Number of subjects: 575
Study 28891788 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 575
Study 25732786 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐tDCS over the left inferior frontal gyrus (IFG)
Number of subjects: 20
Study 25732786 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 20
Study 23827399 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for patients with previous CABG
Number of subjects: 919
Study 23827399 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for patients with previous CABG with ≥1 saphenous vein graft intervention
Number of subjects: 919
Study 23827399 — intervention group
Group type: COMPARATOR
Intervention: Patients without previous CABG
Number of subjects: 919
Study 21115795 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral torezolid phosphate once daily for 5 to 7 days
Number of subjects: 188
Study 21115795 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral torezolid phosphate once daily for 5 to 7 days
Number of subjects: 188
Study 21115795 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral torezolid phosphate once daily for 5 to 7 days
Number of subjects: 188
Study 21115795 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all doses) for patients with S. aureus isolated at baseline
Number of subjects: 188
Study 21115795 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all doses) for patients with MRSA isolated at baseline
Number of subjects: 188
Study 19067789 — intervention group
Group type: EXPERIMENTAL
Intervention: Erectile Dysfunction (ED)
Number of subjects: 3810
Study 17323107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractured leg
Number of subjects: 60
Study 17323107 — intervention group
Group type: COMPARATOR
Intervention: Control leg
Number of subjects: 60
Study 15127203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, individualised diet and exercise
Number of subjects: 490
Study 15127203 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 490
Study 11436945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine 1:25,000
Number of subjects: 60
Study 11436945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine 1:50,000
Number of subjects: 60
Study 11436945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine 1:100,000
Number of subjects: 60
Study 11436945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine 1:200,000
Number of subjects: 60